Skip to main content
SpringerLink
Log in

Antiviral Drugs, Antibodies, and Vaccines for COVID-19

  • Chapter
  • First Online:
Studies to Combat COVID-19 using Science and Engineering

  • 158 Accesses

Abstract

This chapter starts by introducing COVID-19 and its variants. Then it gives brief descriptions of the human immune system and COVID-19 testing methods for antigens and antibodies. Information is also provided about COVID-19 treatments with antiviral drugs and antibodies. Finally, there is a discussion about vaccines including Pfizer, Moderna, and Johnson & Johnson.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eckert, A., & Higgins, D. (2020). File: SARS-CoV-2 without background.png. License: This image is in the public domain. File: SARS-CoV-2 without background.png - Wikimedia Commons.

    Google Scholar 

  2. Howes, L. (2021). What you need to know about SARS-CoV-2 variants. Chemical & Engineering News, 18–19.

    Google Scholar 

  3. Mahase, E. (2021). COVID-19: How many variants are there, and what we know about them? BMJ, 374, n1971. https://doi.org/10.1136/bmj.n1971

    Article  PubMed  Google Scholar 

  4. Zhang, J. M., & An, J. (2007). Cytokines, inflammation, and pain. International Anesthesiology Clinics, 45(2), 27–37. https://doi.org/10.1097/AIA.0b013e318034194e

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Colm, G. (2009). File: Phagocytosis 2.png. License: Creative Commons Attribution-Share Alike 3.0 File: Phagocytosis2.png - Wikimedia Commons.

    Google Scholar 

  6. Rehua. (2012). File: T cell activation.svg. License: This work is in the public domain. File: T cell activation.svg - Wikimedia Commons.

    Google Scholar 

  7. Wang, H., Li, G., Zhao, J., Li, Y., & Ai, Y. (2021). An overview of nucleic acid testing for the novel coronavirus SARS-CoV-2. Frontiers in Medicine, 7, 571709. https://doi.org/10.3389/fmed.2020.571709

    Article  PubMed  PubMed Central  Google Scholar 

  8. U.S. Secretary of Defense. (2021). File: ID Now Testing (51038387158).jpg. License: Creative Commons Attribution 2.0. File:ID Now testing (51038387158).jpg - Wikimedia Commons.

    Google Scholar 

  9. Peplow, M. (2021). Transistor detects SARS-CoV-2 in less than a minute. Chemical & Engineering News, 99, 6.

    Google Scholar 

  10. Rahimi, H., Salehiabar, M., Barsbay, M., Ghaffarlou, M., Kavetskyy, T., Sharafi, A., Davaran, S., Chauhan, S. C., Danafar, H., Kaboli, S., Nosrati, H., Yallapu, M. M., & Conde, J. (2021). CRISPR systems for COVID-19 diagnosis. ACS Sensors, 6(4), 1430–1445. https://doi.org/10.1021/acssensors.0c02312

    Article  CAS  PubMed  Google Scholar 

  11. Peplow, M. (2020). 15 min, $5 COVID-19 test rolls out. Chemical & Engineering News, 98, 4.

    Google Scholar 

  12. CDC. (2021). Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020. MMWR, 70, 100. Retrieved from cdc.gov

    Google Scholar 

  13. Arnold, C. (2021). Sniffing out COVID-19. Chemical & Engineering News, 99, 21–24.

    Google Scholar 

  14. Ruszkiewicz, D., Sanders, D., et al. (2020). Diagnosis of COVID-19 by analysis of breath with gas chromatography-ion mobility spectrometry – A feasibility study. EClinical Medicine, 29, 100609. https://doi.org/10.1016/j.eclinm.2020.100609

    Article  Google Scholar 

  15. Yin, W., Mao, C., Luan, X., Shen, D. D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., Chang, S., Xie, Y. C., Tian, G., Jiang, H. W., Tao, S. C., Shen, J., Jiang, Y., Jiang, H., Xu, Y., Zhang, S., Xu, H. E. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science (New York, N.Y.), 368(6498), 1499–1504. https://doi.org/10.1126/science.abc1560

    Article  CAS  Google Scholar 

  16. Howes, L. (2020). How remdesivir blocks SARS-CoV-2. Chemical & Engineering News, 98, 10.

    Google Scholar 

  17. Deb, S., Reeves, A. A., Hopefl, R., & Bejusca, R. (2021). ADME and pharmacokinetic properties of remdesivir: Its drug interaction potential. Pharmaceuticals (Basel, Switzerland), 14(7), 655. https://doi.org/10.3390/ph14070655

    Article  CAS  Google Scholar 

  18. Boghog. (2020). File: Remdesivir activation.svg. License: Creative Commons Attribution- Share Alike 4.0 International. File:Remdesivir activation.svg - Wikimedia Commons.

    Google Scholar 

  19. Satyanarayana, M. (2021). Two COVID-19 antiviral pills advance to late-stage trials. Chemical & Engineering News, 99, 11.

    Google Scholar 

  20. Kabinger, F., Stiller, C., Schmitzová, J., et al. (2021). Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology, 28, 740–746. https://doi.org/10.1038/s41594-021-00651-0

    Article  CAS  Google Scholar 

  21. Dolgin, E. (2021). The race for antiviral drugs to beat COVID—and the next pandemic. Nature, 592, 340–343.

    Article  CAS  Google Scholar 

  22. Cross, R. (2020). FDA authorizes COVID-19 antibody therapy. Chemical & Engineering News, 15.

    Google Scholar 

  23. Cross, R. (2020). Rapid antibody development came of age. Chemical & Engineering News, 39.

    Google Scholar 

  24. Taylor, P. C., Adams, A. C., Hufford, M. M., et al. (2021). Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews. Immunology, 21, 382–393. https://doi.org/10.1038/s41577-021-00542-x

    Article  CAS  PubMed  Google Scholar 

  25. Renn, A., Fu, Y., Hu, X., Hall, M. D., & Simeonov, A. (2020). Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends in Pharmacological Sciences, 41, 815–829.

    Article  CAS  Google Scholar 

  26. Shanmugaraj, B., Siriwattananon, K., Wangkanont, K., & Phoolcharoen, W. (2020). Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). Asian Pacific Journal of Allergy and Immunology, 38, 10–18.

    CAS  PubMed  Google Scholar 

  27. Fvasconcellos. (2020). File: REGN-COV2 binding SARS-CoV-2 spike protein.png. License: This work is in the public domain. File:REGN-COV2 binding SARS-CoV-2 spike protein.png - Wikimedia Commons.

    Google Scholar 

  28. Weinreich, D., Sivapalasingam, S., et al. (2021). REGN-CoV2, a neutralizing antibody cocktail, in outpatients with COVID-19. NEJM, 384, 238.

    Article  CAS  Google Scholar 

  29. Gupta, A., Gonzalez-Rojas, Y., et al. (2021). Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. The New England Journal of Medicine, 385, 1941. https://doi.org/10.1056/NEJMoa2107934

    Article  CAS  PubMed  Google Scholar 

  30. Cross, R. (2021). Third COVID-19 antibody is authorized. Chemical & Engineering News, 99, 11.

    Google Scholar 

  31. HHS. (n.d.). Vaccine types. Author. Retrieved from HHS.gov

  32. Kramer, A. (2021). Russia’s vaccine is safe and effective, published study shows. The New York Times. Retrieved from nytimes.com

  33. Cross, R. (2021). AstraZeneca, Gamaleya, Novavax, and J & J post positive vaccine results. Chemical & Engineering News, 99, 4–5.

    CAS  Google Scholar 

  34. Satyanarayana, M. (2021). FDA approves the Pfizer-BioNTech COVID-19 vaccine. Chemical & Engineering News, 99, 10.

    Article  Google Scholar 

  35. Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Jr., Hammitt, L. L., & C4591001 Clinical Trial Group. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 1761–1773.

    Article  Google Scholar 

  36. Cross, R. (2020). Pfizer COVID-19 vaccine rolls out across the U.S. Chemical & Engineering News, 98, 4–5.

    Google Scholar 

  37. U.S. Food and Drug Administration and Pfizer Inc. (2020). File: BNT162b2 vaccine efficacy data.png. License: This work is in the public domain. File:BNT162b2 vaccine efficacy data.png - Wikimedia Commons.

    Google Scholar 

  38. Health Canada. (2020). Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies. Author.

    Google Scholar 

  39. Cott, E., deBruyn, E., & Corum, J. (2021). How Pfizer makes its COVID-19 vaccine. The New York Times. Retrieved from nytimes.com

  40. Weise, E., & Weintraub, K. (2021). A COVID-19 vaccine life cycle: From DNA to doses. USA Today. How a COVID vaccine is made: The step-by-step journey of a Pfizer dose. Retrieved from usatoday.com

  41. Cross, R. (2020). Moderna says COVID-19 vaccine is 94.5% effective in preliminary analysis. Chemical & Engineering News, 98, 4–5.

    Google Scholar 

  42. Cross, R. (2021). Moderna’s COVID-19 vaccine to rollout across the US. Chemical & Engineering News, 99, 10.

    Article  Google Scholar 

  43. Mullin, R. (2021). Moderna announces plans to make vaccines in Africa. Chemical & Engineering News, 99, 13.

    Google Scholar 

  44. Livingston, E. H., Malani, P. N., & Creech, C. B. (2021). The Johnson & Johnson vaccine for COVID-19. Journal of the American Medical Association, 325(15), 1575. https://doi.org/10.1001/jama.2021.2927

    Article  CAS  PubMed  Google Scholar 

  45. Cross, R. (2021). US authorizes J & J vaccine. Chemical & Engineering News, 99, 5.

    Article  Google Scholar 

  46. CDC. (2021). Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions — United States, March–August 2021. MMWR, 70, 1337. Retrieved from cdc.gov

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Electrical & Computer Engineering, Clarkson University, Potsdam, NY, USA

    Dana Barry

  2. State University of New York at Canton, Canton, NY, USA

    Dana Barry

  3. National Institute of Technology, Suzuka College, Shiroko-cho, Suzuka, Suzuka, Mie, Japan

    Hideyuki Kanematsu

Authors
  1. Dana Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideyuki Kanematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dana Barry .

Editor information

Editors and Affiliations

  1. Department of Electrical & Computer Engineering, Clarkson University, Potsdam, NY, USA

    Dana Barry

  2. National Institute of Technology, Suzuka College, Shiroko-cho, Suzuka, Mie, Japan

    Hideyuki Kanematsu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barry, D., Kanematsu, H. (2022). Antiviral Drugs, Antibodies, and Vaccines for COVID-19. In: Barry, D., Kanematsu, H. (eds) Studies to Combat COVID-19 using Science and Engineering. Springer, Singapore. https://doi.org/10.1007/978-981-19-1356-3_10

Download citation

Publish with us

Policies and ethics

Search

Navigation